Reuters logo
Exelixis cancer drug meets key goal in late-stage trial
2017年10月16日 / 上午11点17分 / 1 个月前

Exelixis cancer drug meets key goal in late-stage trial

Oct 16 (Reuters) - Exelixis Inc said on Monday its drug met the main goal in a late stage study for treating patients with a type of liver cancer.

The drug, Cabometyx, showed statistically significant improvement in overall survival in patients with advanced hepatocellular carcinoma, compared with a placebo.

Cabometyx was approved to treat kidney cancer in 2016. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Anil D‘Silva)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below